02419nas a2200289   4500008004100000022001400041245021900055210006900274260000800343300001400351490000800365520151100373100001601884700001401900700001601914700002001930700001801950700001301968700001501981700001201996700001302008700001502021700001402036700001702050700001802067856004402085       2010                        eng d  a1528-002000aImmune monitoring with iTAg MHC Tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study.0 aImmune monitoring with iTAg MHC Tetramers for prediction of recu  cSep  a1655 - 620 v1163 aCytomegalovirus (CMV) infection is an important cause of morbidity and mortality in hematopoietic stem cell transplant recipients despite the introduction of posttransplantation viral monitoring and preemptive antiviral therapy. We evaluated the use of HLA class I tetramers in monitoring CMV-specific T-cell recovery to predict patients at risk for CMV-related complications. This prospective multicenter clinical trial obtained nearly 1400 tetramer/allele results in more than 800 biweekly blood samples from 83 patients monitored for 1 year after transplantation. Major HLA types were included (A*0101, A*0201, B*0702, B*0801, B*3501). iTAg MHC Tetramers (Beckman Coulter) were used to enumerate CMV-specific CD8(+) T cells by flow cytometry using a single-platform absolute counting method. Assay variability was 8% or less and results were available within 3 hours. Delayed recovery of CMV-specific T cells (< 7 cells/μL in all blood samples during the first 65 days after transplantation) was found to be a significant risk factor for CMV-related complications; these patients were more likely to develop recurrent or persistent CMV infection (relative risk 2.6, CI 1.2-5.8, P = .01) than patients showing rapid recovery, which was associated with protection from CMV-related complications (P = .004). CMV tetramer-based immune monitoring, in conjunction with virologic monitoring, can be an important new tool to assess risk of CMV-related complications and to guide preemptive therapeutic choices.1 aGratama, JW1 aBoeckh, M1 aNakamura, R1 aCornelissen, JJ1 aBrooimans, RA1 aZaia, JA1 aForman, SJ1 aGaal, K1 aBray, KR1 aGasior, GH1 aBoyce, CS1 aSullivan, LA1 aSouthwick, PC  uhttps://notifylibrary.org/reference/605